Evidence map›Paper›PMID 35212829›Full record

Observational studyInternational journal of clinical oncology2022

A prospective observational study of postoperative adjuvant chemotherapy for non-small cell lung cancer in elderly patients (≥ 75 years).

Tokujiro Yano, Motoharu Hamatake, Shoji Tokunaga, Tatsuro Okamoto, Koji Yamazaki, Takashi Miura, Takeshi Nagayasu, Masami Sato, Seiichi Fukuyama, Kenji Sugio and 1 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Tokujiro YanoDepartment of General Thoracic Surgery, National Hospital Organization Beppu Medical Center, 1473 Uchikamado, Beppu, 874-0011, Japan. yano.tokujiro.ej@mail.hosp.go.jp.
Motoharu HamatakeDepartment of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Shoji TokunagaMedical Information Center, Kyushu University Hospital, Fukuoka, Japan.
Tatsuro OkamotoDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Koji YamazakiDepartment of Thoracic Surgery and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Takashi MiuraDepartment of Thoracic Surgery, Oita City Medical Association's Almeida Hospital, Oita, Japan.
Takeshi NagayasuDepartment of Surgical Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Masami SatoDepartment of Thoracic Surgery, Kagoshima University, Kagoshima, Japan.
Seiichi FukuyamaDepartment of General Thoracic Surgery, National Hospital Organization Beppu Medical Center, 1473 Uchikamado, Beppu, 874-0011, Japan.
Kenji SugioDepartment of Thoracic and Breast Surgery, Faculty of Medicine, Oita University, Yufu, Japan.
Lung Oncology Group in Kyushu (LOGIK)
Beppu Medical Center · JPKagoshima University · JPKitakyushu Municipal Medical Center · JPKyushu University Hospital · JPNagasaki University · JPNational Hospital Organization Kyushu Cancer Center · JPNational Kyushu Medical Center · JPOita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo examine the effects of postoperative adjuvant chemotherapy for elderly (≥ 75 years of age) patients with completely resected non-small cell lung cancer (NSCLC), we conducted a multi-institutional and prospective observational study.

methodsPatients were recruited between January 2014 and December 2017, and assigned to two cohort groups based on the patients' choice either to receive postoperative adjuvant chemotherapy (Cohort B) or not (Cohort A). All the patients were observed for 2 years after enrollment. The primary endpoint was the postoperative change of Karnofsky Performance Status (KPS) at 2 years. The secondary endpoints were postoperative recurrence-free survival (RFS) and overall survival (OS) at 2 years, and the completion rate of the adjuvant chemotherapy.

resultsTwo hundred and seventy-two patients were enrolled (Cohort A, n = 225; Cohort B, n = 47). At any time point after surgery, no marked difference of KPS was observed between Cohort B and Cohort A. The RFS at 2 years was 70.8% (95% confidence interval [CI], 64.3-76.4) in Cohort A and 76.0% (95% CI 60.8-85.9) in Cohort B. The OS at 2 years was 85.9% (95% CI 80.4-89.9) in Cohort A and 89.1% (95% CI 75.8-95.3) in Cohort B. The completion rate of planned chemotherapy was 49.9% (95% CI 34.1-63.9%).

conclusionsThe elderly patients were not likely to choose to receive postoperative adjuvant chemotherapy; however, no significant adverse effect on postoperative KPS was identified.

trial registrationClinical Trial Registration ID: UMIN000020736.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantHumansNeoplasm StagingElderly patientsKarnofsky performance statusNon-small cell lung cancerPostoperative adjuvant chemotherapySurgery

Identifiers

PMID35212829
OpenAlexW4214552317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.